Varisco Pierre-Alain, So Alexander
Rev Med Suisse. 2014 Jan 22;10(414):187-91.
In the last 15 years, the therapeutical options for the treatment of chronic inflammatory diseases in rheumatology have increased a lot. Nevertheless, some patients do not respond or respond partially to the current therapies--including to the biologics therapy. Tofacitinib (Xeljanz) is now on the Swiss market. It inhibits the JAK pathway. Tofacitinib--as monotherapy or with methotrexate--improves the control of rheumatoid arthritis (RA). In a comparative study, tofacitinib was as effective as adalimumab. Further, tofacitinib reduced structural damages in RA and is considered as an alternative, in case of non-response, to anti-TNF and probably to other biologics therapy. The side effects are upper respiratory tract and opportunist infections and tuberculosis. Blood count, lipids, kidney function, liver tests, CK and blood pressure have to be monitored.
在过去15年里，风湿病学中慢性炎症性疾病的治疗选择大幅增加。然而，一些患者对当前疗法（包括生物制剂疗法）没有反应或仅部分有反应。托法替布（尚杰）现已在瑞士上市。它抑制JAK通路。托法替布作为单一疗法或与甲氨蝶呤联合使用，可改善类风湿关节炎（RA）的控制情况。在一项对比研究中，托法替布与阿达木单抗效果相当。此外，托法替布可减少RA中的结构损伤，在无反应的情况下，被视为抗TNF疗法以及可能其他生物制剂疗法的替代选择。其副作用为上呼吸道感染、机会性感染和结核病。必须监测血细胞计数、血脂、肾功能、肝功能检查、肌酸激酶和血压。
